WATERTOWN, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that Nancy Lurker, Chief Executive Officer of EyePoint Pharmaceuticals, will present at two upcoming virtual conferences:
- Jefferies London Healthcare Conference
Forum: Corporate Presentation
Date: Thursday, November 18, 2021
Time: 3:00 a.m. ET
- 33rd Annual Piper Sandler Virtual Healthcare Conference
Forum: Corporate Presentation
Date: Monday, November 22nd, 2021
Time: 10:00 a.m. ET
A webcast and subsequent archived replay of each corporate presentation may be accessed via the Investors section of the Company website at www.eyepointpharma.com. The Jefferies presentation replay will be available for 30 days after the event, and the Piper Sandler presentation will be available for 90 days after the event.
About EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, a potential twice-yearly sustained delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. The Company has two commercial products: YUTIQ®, for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU®, for the treatment of postoperative inflammation following ocular surgery. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts. To learn more about the Company, please visit www.eyepointpharma.com and connect on Twitter and LinkedIn.
Investors:
Christina Tartaglia
Stern IR
Direct: 212-698-8700
christina.tartaglia@sternir.com
Media Contact
Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com
Source: EyePoint Pharmaceuticals, Inc.
